Immunogenomics Facility

Welcome to the Leeds Immunogenomics Facility (IGF) 

UK’s First Core Facility to Run Olink® Target Assays

We use Olink® proteomics technology for targeted protein biomarker research, providing new insights into disease, improving disease detection and helping to understand disease biology. 

Learn how Olink® Proximity Extension Assay (PEA) technology works.

Why Olink?
•    Rapid, high-throughput protein analysis
•    Curated panels of protein biomarkers
•    Exceptional sensitivity and specificity
•    Minimal sample consumption
•    Strict assay technical validation and quality control procedures
•    Cited in +1600 publications since 2014

Contact us for advice on project design, costs/estimates for grant applications or quotations for work to be carried out in the short-term.

Olink® PEA Technology

Next-Gen Technology for Highly Accurate, Multiplex Protein Analysis

Olink utilises proprietary Proximity Extension Assay (PEA) technology, which combines immunoaffinity with a genomics readout (e.g., qPCR) to measure proteins with exceptional throughput, sensitivity, and specificity.

Paired antibodies conjugated to complementary oligonucleotide sequences come in close proximity only when they both bind to their specific target protein (see Figure 1 below).

The complementary oligonucleotides hybridize, creating a unique double-stranded barcode for the protein and sample, and then are extended and amplified via PCR. For Olink® Target 96 and 48 platforms, the amplicons are measured using qPCR and are quantitatively proportional to the initial concentration of the target protein.

The cycle threshold (Ct) values generated from qPCR are translated into relative quantification units known as Normalised Protein eXpression (NPX) values using a series of computations, which minimise technical variation and improve interpretability of results. Importantly, the technical performance of the assay is ascertained using a built-in QC system using internal, spiked-in controls. 

Watch a 3-minute animation of Olink PEA technology: 

<iframe width="560" height="315" src="" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" allowfullscreen></iframe>

Olink® Target 96 and 48

Innovative Platform for Human Protein Biomarker Discovery, Development and Validation

Target 96

•    Choose from 15 carefully designed panels available for human (14) and mouse (1)
•    Each panel is focused on a specific area of disease or key biological process
•    Broad library of over 1100 established or exploratory protein biomarkers
•    Measurement of 92 protein biomarkers simultaneously for up to 88 samples with each panel
•    Uses only 1 µL of biological sample per panel
•    Results provided in Normalised Protein eXpression (NPX) values (i.e., relative quantification)

Target 48
•    Simultaneous analysis of 45 protein biomarkers for up to 42 samples
•    Targets proteins (i.e., cytokines) associated with inflammation
•    Uses only 1 µL per biological sample 
•    Results reported in standard concentration units (pg/mL) or relative quantification (NPX units)

Click on the panels listed below to see the protein assay list and validation data.

Target 96  Organ Damage   – Development   –  Metabolism    – Cell regulation   – Cardiometabolic    – Cardiovascular II   – Cardiovascular III   –  Immuno-Oncology  – Immune    –  Response    –  Neuro Exploratory  –  Neurology   -  Oncology II   – Oncology III  -  Inflammation   –  Mouse Exploratory
Target 48 Cytokine
Focus Up to 21 biomarkers
Flex Up to 21 biomarkers from ~200 pre-validated